Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Publication | Closed Access

DOI

Citations

References

2017

Year

Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Joseph de Wet, Jürgen K. Rockstroh, Adriano Lazzarin,

The Lancet HIV

Phase 3BTreatment And PreventionMedicineAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapyHiv-1 InfectionAntiviral DrugHivPharmacologyTenofovir Disoproxil FumarateDrug Resistance